Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders
Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered nontraditional cardiovascular risk factors.Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2023-11-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5569 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250001583079424 |
|---|---|
| author | E. P. Kolesova D. A. Usoltsev E. V. Moguchaia M. A. Boyarinova A. M. Erina K. M. Tolkunova A. L. Maslyanskiy A. V. Mazing S. V. Kibkalo E. Yu. Vasileva N. S. Novikova E. I. Ermolenko N. N. Artemov O. P. Rotar A. O. Konradi E. V. Shlyakhto |
| author_facet | E. P. Kolesova D. A. Usoltsev E. V. Moguchaia M. A. Boyarinova A. M. Erina K. M. Tolkunova A. L. Maslyanskiy A. V. Mazing S. V. Kibkalo E. Yu. Vasileva N. S. Novikova E. I. Ermolenko N. N. Artemov O. P. Rotar A. O. Konradi E. V. Shlyakhto |
| author_sort | E. P. Kolesova |
| collection | DOAJ |
| description | Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered nontraditional cardiovascular risk factors.Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years.Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out.Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ³1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns.Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries. |
| format | Article |
| id | doaj-art-a688ec8bd6d345e5b1a99341cb08d8ac |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2023-11-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-a688ec8bd6d345e5b1a99341cb08d8ac2025-08-20T03:57:22Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202023-11-01281110.15829/15604071-2023-55693901Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disordersE. P. Kolesova0D. A. Usoltsev1E. V. Moguchaia2M. A. Boyarinova3A. M. Erina4K. M. Tolkunova5A. L. Maslyanskiy6A. V. Mazing7S. V. Kibkalo8E. Yu. Vasileva9N. S. Novikova10E. I. Ermolenko11N. N. Artemov12O. P. Rotar13A. O. Konradi14E. V. Shlyakhto15Almazov National Medical Research CenterAlmazov National Medical Research Center; St. Petersburg National Research University of Information Technologies, Mechanics and OpticsAlmazov National Medical Research CenterAlmazov National Medical Research CenterAlmazov National Medical Research CenterAlmazov National Medical Research CenterAlmazov National Medical Research CenterPavlov First St. Petersburg State Medical UniversityAlmazov National Medical Research Center; Pavlov First St. Petersburg State Medical UniversityAlmazov National Medical Research CenterInstitute of Experimental MedicineInstitute of Experimental MedicineAlmazov National Medical Research Center; St. Petersburg National Research University of Information Technologies, Mechanics and OpticsAlmazov National Medical Research CenterAlmazov National Medical Research CenterAlmazov National Medical Research CenterSurrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered nontraditional cardiovascular risk factors.Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years.Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out.Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ³1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns.Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries.https://russjcardiol.elpub.ru/jour/article/view/5569zonulincalprotectinmetabolic disorderstarget organ damage |
| spellingShingle | E. P. Kolesova D. A. Usoltsev E. V. Moguchaia M. A. Boyarinova A. M. Erina K. M. Tolkunova A. L. Maslyanskiy A. V. Mazing S. V. Kibkalo E. Yu. Vasileva N. S. Novikova E. I. Ermolenko N. N. Artemov O. P. Rotar A. O. Konradi E. V. Shlyakhto Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders Российский кардиологический журнал zonulin calprotectin metabolic disorders target organ damage |
| title | Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders |
| title_full | Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders |
| title_fullStr | Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders |
| title_full_unstemmed | Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders |
| title_short | Association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders |
| title_sort | association of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage in a sample of patients with metabolic disorders |
| topic | zonulin calprotectin metabolic disorders target organ damage |
| url | https://russjcardiol.elpub.ru/jour/article/view/5569 |
| work_keys_str_mv | AT epkolesova associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT dausoltsev associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT evmoguchaia associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT maboyarinova associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT amerina associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT kmtolkunova associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT almaslyanskiy associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT avmazing associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT svkibkalo associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT eyuvasileva associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT nsnovikova associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT eiermolenko associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT nnartemov associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT oprotar associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT aokonradi associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders AT evshlyakhto associationoffecalzonulinandcalprotectinlevelswithcardiovascularriskfactorsandtargetorgandamageinasampleofpatientswithmetabolicdisorders |